These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 27831592)

  • 1. Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants.
    Raparelli V; Proietti M; Cangemi R; Lip GY; Lane DA; Basili S
    Thromb Haemost; 2017 Jan; 117(2):209-218. PubMed ID: 27831592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
    Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
    Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients.
    Dillinger JG; Aleil B; Cheggour S; Benhamou Y; Béjot Y; Marechaux S; Delluc A; Bertoletti L; Lellouche N
    Arch Cardiovasc Dis; 2018 Feb; 111(2):85-94. PubMed ID: 28988597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation.
    Yao X; Abraham NS; Alexander GC; Crown W; Montori VM; Sangaralingham LR; Gersh BJ; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26908412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association.
    Hernández Madrid A; Potpara TS; Dagres N; Chen J; Larsen TB; Estner H; Todd D; Bongiorni MG; Sciaraffia E; Proclemer A; Cheggour S; Amara W; Blomstrom-Lundqvist C
    Europace; 2016 Mar; 18(3):463-7. PubMed ID: 26899998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P
    Europace; 2015 Oct; 17(10):1467-507. PubMed ID: 26324838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
    Deitelzweig S
    Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectively Initiating and Maintaining Anticoagulation in Patients With Atrial Fibrillation.
    Wang TY
    Circulation; 2019 Apr; 139(15):1763-1765. PubMed ID: 30958715
    [No Abstract]   [Full Text] [Related]  

  • 11. Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey.
    Larsen TB; Potpara T; Dagres N; Proclemer A; Sciarrafia E; Blomström-Lundqvist C;
    Europace; 2015 May; 17(5):819-24. PubMed ID: 25926476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.
    Camm AJ; Fox KAA; Peterson E
    Europace; 2018 Jan; 20(1):1-11. PubMed ID: 29040518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics And Health Care Resources In Patients Treated With Oral Anticoagulants: Evidences From Italian Administrative Databases.
    Degli Esposti L; Andretta M; Di Pasquale G; Gambera M; Saragoni S; Perrone V; Buda S
    Vasc Health Risk Manag; 2019; 15():429-437. PubMed ID: 31632047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk profiles and pattern of antithrombotic use in patients with non-valvular atrial fibrillation in Thailand: a multicenter study.
    Krittayaphong R; Winijkul A; Methavigul K; Wongtheptien W; Wongvipaporn C; Wisaratapong T; Kunjara-Na-Ayudhya R; Boonyaratvej S; Komoltri C; Kaewcomdee P; Yindeengam A; Sritara P;
    BMC Cardiovasc Disord; 2018 Aug; 18(1):174. PubMed ID: 30144802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct oral anticoagulants use in elderly patients with non valvular atrial fibrillation: state of evidence.
    Benedetti G; Neccia M; Agati L
    Minerva Cardioangiol; 2018 Jun; 66(3):301-313. PubMed ID: 29125269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
    Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of SAMe-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists.
    Abumuaileq RR; Abu-Assi E; Raposeiras-Roubin S; López-López A; Redondo-Diéguez A; Álvarez-Iglesias D; Rodríguez-Mañero M; Peña-Gil C; González-Juanatey JR
    Europace; 2015 May; 17(5):711-7. PubMed ID: 25662984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants.
    Gallù M; Marrone G; Legramante JM; De Lorenzo A; Di Daniele N; Noce A
    Cardiovasc Ther; 2020; 2020():1743927. PubMed ID: 32684980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient Adherence to Novel Oral Anticoagulants (NOACs) for the Treatment of Atrial Fibrillation and Occurrence of Associated Bleeding Events: A Systematic Review and Meta-analysis.
    Shehab A; Bhagavathula AS; Abebe TB; Abegaz TM; Elnour AA; Sabbour HM; Uzzafer M; Hersi A; Hamad AK
    Curr Vasc Pharmacol; 2019; 17(4):341-349. PubMed ID: 29359674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study.
    Liu T; Yang HL; Gu L; Hui J; Omorogieva O; Ren MX; Wang XH
    BMC Cardiovasc Disord; 2020 Jan; 20(1):22. PubMed ID: 31948390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.